Aumolertinib in Treatment-Naive EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY

被引：0
|
作者：
Zhang, X. [1 ]
Zhang, M. [1 ]
Wei, C. [1 ]
Du, X. [1 ]
Zhang, G. [1 ]
Niu, Y. [1 ]
Yan, X. [1 ]
Yang, J. [1 ]
Wang, H. [1 ]
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Affiliated Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Brain metastases; dose escalation; aumolertinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.12A.05
引用
收藏
页码：S194 / S194
页数：1
相关论文
共 50 条
  • [1] Aumolertinib in Treatment-Naive EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S397 - S398
  • [2] Dacomitinib in treatment-naive EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
    Yu, Y.
    Pan, Y.
    Zhou, J.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1694
  • [3] High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
    Fan, Y.
    Zhu, J.
    He, J.
    Zhou, R.
    Chen, J.
    Han, G.
    Ren, B. Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1585 - S1585
  • [4] The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S646 - S647
  • [5] Safety and Efficacy of Cranial Radiotherapy in Combination with Aumolertinibin EGFR-Mutant NSCLC Patients with Brain Metastases
    Han, S.
    Wang, W.
    Bi, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S590 - S590
  • [6] A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases
    He, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S490 - S490
  • [7] Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study
    Meng, X.
    Kong, L.
    Zhao, K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S581 - S581
  • [8] Optimal treatment sequence for untreated EGFR-mutant NSCLC with brain metastases
    Miyawaki, Eriko
    Kenmotsu, Hirotsugu
    Harada, Hideyuki
    Mitsuya, Koichi
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakasu, Yoko
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Outcomes of EGFR-mutant NSCLC patients with de novo brain metastases by upfront treatment
    Ma, J.
    Li, Y.
    Lai, G. G. Y.
    Tan, E-H.
    Lim, W. D. T.
    Ang, M-K.
    Ng, Q. S.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Fong, K. W.
    Siow, T. R.
    Thiagarajan, A.
    Yap, S. P.
    Chia, S. H. B.
    Ng, W. L.
    Tan, D. S. W.
    Tan, S. H.
    Tan, W. L.
    Chua, K. L. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S970 - S970
  • [10] Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases
    Nadler, E.
    Pavilack, M.
    Espirito, J.
    Baidoo, B.
    Fernandes, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S383 - S383
12345